Gilead reported 2025 revenue of $29.44 billion and Q1 2026 revenue of $6.96 billion. The thesis turns on whether HIV durability and cash generation can keep funding oncology, inflammation and pipeline expansion while patent, clinical and debt risks stay controlled.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-20 · Issuer identity, ticker, exchange and CIK.SEC APISEC submissions APIRetrieved 2026-05-20 · Company identity, filing chronology and filing metadata.SEC XBRL APISEC companyfacts APIRetrieved 2026-05-20 · XBRL financial statement baseline.Annual reportGilead Sciences, Inc. annual report2026-02-24 · Annual business, risk and financial baseline.Quarterly reportGilead Sciences, Inc. latest quarterly report2026-05-07 · Latest interim financial baseline.Current reportGilead Sciences, Inc. Form 8-K2026-05-07 · Recent company filing chronology.Proxy statementGilead Sciences, Inc. proxy statement2026-03-20 · Governance and incentive context.